SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as the community discusses its potential for further upside, fueled by Wedbush's bullish stance and speculation around robotaxi progress; some are pointing to insider selling and EV competition as reasons to be cautious. Community members are actively debating the stock's valuation, future prospects, and potential price targets. Technical analysis chatter is focused on key levels and chart patterns to determine likely direction.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is trending due to positive preliminary analysis showing an 80% reduction in breast cancer recurrence, sparking excitement among investors. The community is actively discussing the potential for a short squeeze given the high short interest and low float, with some speculating on a buyout. Many express strong conviction in the company's financials and the potential of its breast cancer drug, while others debate the significance of the open-label data.

ARB IOT Group Ltd. is a holding company that engages in the provision of solutions for the integration of IoT systems and devices. It operates through the Internet of Things and Investment Holding and Others segments. The company was founded on March 1, 2022 and is headquartered in Singapore.

ARB IOT Group Ltd

ARBB is trending amid community discussions about its low float and potential for a short squeeze, with some traders eyeing a possible breakout. Chatter suggests the stock may be influenced by broader market trends and speculative trading strategies. Others are closely monitoring key price levels, anticipating a volatile trading session.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power Corp is trending as investors discuss its potential role in powering AI data centers, particularly given the urgent need for power in future hyperscale facilities. Community sentiment is mixed, with some highlighting the company's NRC-certified design as a key advantage, while others express concerns about commercialization, costs, and execution. Discussions also include Fluor's stake monetization and an upcoming shareholder vote that could significantly impact the stock.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is trending as investors react to reports of a potential $7 billion acquisition of cybersecurity firm Armis, with some analysts downgrading the stock. The community is debating whether the company is overvalued, especially given KeyBanc's recent underweight rating and price target. Despite strategic partnerships and AI initiatives, the stock has underperformed this year, leading to discussions about its growth prospects and valuation in the face of increasing competition.

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Kyverna Therapeutics Inc.

Kyverna Therapeutics is trending after reporting positive Phase 2 trial results for its CAR-T cell therapy in stiff person syndrome, leading to plans for a BLA submission in 1H 2026.  The community is discussing the potential of miv-cel to become the first approved therapy for SPS and the first CAR T treatment for autoimmune disease, while also highlighting the company's strong financial position and acquisition potential. Some are concerned about the niche market affecting sales and stability, while others are excited about the possibility of a double-digit valuation.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Fueled by reports of potential federal cannabis reclassification under a Trump executive order, Tilray is trending as investors anticipate regulatory reform, sparking bullish sentiment. The community is actively discussing potential benefits like tax relief and easier access to funding, while also weighing the possibility of a 'sell-the-news' event. With high short interest and comparisons to past cannabis rallies, the stock is experiencing significant volatility as the sector anticipates major regulatory changes.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

The AdvisorShares Pure US Cannabis ETF ($MSOS) is surging amid renewed speculation that the federal government may reclassify marijuana, potentially offering tax relief and boosting profitability for cannabis businesses. Community discussions revolve around whether this time is different, with many citing past false starts and the need for confirmed news before fully trusting the rally. The sector-wide move is also drawing attention to specific stocks that could benefit most from the shift.

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.

Immunome Inc

IMNM is trending following positive Phase 3 trial results for its desmoid tumor treatment, varegacestat, sparking discussions about its potential market value compared to similar drugs. The community is focused on the drug's efficacy data and analyst ratings, particularly those highlighting improved chemistry over existing treatments. Some investors are considering securing profits amidst the volatility.

Mask Network is the core product of Dimension, which is positioned to become the bridge that connects internet users from Web 2.0 to Web 3.0. The foundational technology of Mask Network is a peer-to-peer encrypted messaging application, with new functions continuously being created around this foundation. We at Mask Network are strong believers in the ownership economy. People should own what they produce, people should own their data, their attention and the virtual space they choose to contribute to.  Mask Network integrates decentralized social messaging, borderless payment network, and decentralized file storage and sharing to provide a safe and convenient portal for users to jump right into the continent of decentralized finance and then the new world of Web 3.0.

Mask Network

MASK is surging amid chatter about its connection to web3 and decentralized social media, fueled by its recent price action and high trading volume. Community members are speculating about potential integrations and upcoming catalysts, with some drawing comparisons to other high-flying altcoins. The focus remains on whether MASK can break through resistance levels and sustain its upward momentum in the current market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics for chronic organ failure and cancer. GCS-100, the Company's lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer. LJPC-501, the Company's second product candidate, is a natural peptide for the treatment of the hepatorenal syndrome.

LJPC
La Jolla Pharmaceutical Co.

Feed

News

Sentiment

Fundamentals

Info

Latest LJPC News

LJPCLa Jolla Pharmaceutical Co.